Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020)

Kymera Therapeutics (KYMR) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $25.5 million as the latest value for Q2 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $25.5 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $25.5 million through Jun 2020, changed N/A year-over-year, with the annual reading at $29.2 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q2 2020 was $25.5 million at Kymera Therapeutics, down from $29.2 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $38.7 million in Q3 2019, with the low at $25.5 million in Q2 2020.